Acadia Healthcare Q4 revenue beats on volume growth; posts loss due to impairment charge

Acadia Healthcare

25/02/2026 12:19

Overview

Behavioral healthcare provider's Q4 revenue grew 6.1%, beating analyst expectations

Adjusted EBITDA for Q4 missed analyst expectations

Company added 181 newly licensed beds in Q4, expanding capacity

Outlook

Acadia forecasts full-year 2026 revenue between $3.37 bln and $3.45 bln

Company expects adjusted EBITDA for 2026 to range from $575 mln to $610 mln

Acadia anticipates first-quarter 2026 revenue between $820 mln and $830 mln

Result Drivers

VOLUME GROWTH - Revenue growth driven by a 3.1% increase in patient days and 1.3% increase in revenue per patient day

CAPACITY EXPANSION - Added 181 newly licensed beds, including 144 from new facilities, enhancing capacity

GOODWILL IMPAIRMENT - Net loss driven by a $996.2 million non-cash goodwill impairment charge

Company press release: ID:nBw10bKbha

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$821.46 mln
$800.06 mln (12 Analysts)
Q4 Net Income
-$1.18 bln
Q4 Adjusted EBITDA
Miss
$99.80 mln
$102.90 mln (13 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Acadia Healthcare Company Inc is $18.50, about 7.7% above its February 24 closing price of $17.17

The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 8 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)